Celltrion Reports Positive Data For High-Concentration Adalimumab

Phase III Trials Cover Two Delivery Methods For CT-P17

Needle pen
Celltrion’s trials demonstrated the safety and efficacy of its high-concentration adalimumab biosimilar • Source: Shutterstock

More from Biosimilars

More from Products